Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) released its quarterly earnings results on Thursday. The company reported ($5.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by ($3.45), FiscalAI reports. The company had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Phase 3 myelofibrosis readout in March 2026: Karyopharm expects top-line data from its frontline selinexor + ruxolitinib (CENTURY/SENTRI) trial next month, positioning the combo to be the first frontline combination and a potential major value driver if positive.
• Phase 3 endometrial cancer data mid‑2026: The EXPORT‑EC042 trial remains on track for mid‑2026 top‑line results, supported by promising long‑term SIENNA subgroup data in P53 wild‑type/pMMR patients that Karyopharm highlights as a meaningful expansion opportunity.
• Near‑term cash runway into Q2 2026: The company ended 2025 with ~$64.1M in cash and says existing liquidity funds operations only into the second quarter, and it is actively evaluating financing and strategic options to bridge to and beyond upcoming readouts.
• Commercial performance and 2026 guidance: Xpovio net product revenue grew to $114.9M in 2025, management expects $115M–$130M in 2026 and continues to position Xpovio in community and peri‑T‑cell engager settings as a durable commercial foundation.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock traded up $1.88 during trading hours on Thursday, reaching $9.25. The company had a trading volume of 1,386,142 shares, compared to its average volume of 467,340. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $10.38. The firm has a market cap of $169.33 million, a price-to-earnings ratio of -0.64 and a beta of 0.21. The company has a 50 day moving average of $6.86 and a 200 day moving average of $6.18.

Analyst Ratings Changes

A number of research firms recently issued reports on KPTI. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating for the company. Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada dropped their price objective on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock valued at $1,382,000 after acquiring an additional 94,445 shares during the last quarter. Bank of America Corp DE boosted its stake in Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after acquiring an additional 35,626 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $163,000. ADAR1 Capital Management LLC bought a new stake in Karyopharm Therapeutics in the third quarter valued at approximately $164,000. Finally, XTX Topco Ltd bought a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $56,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.